

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 66118

**Title:** Frontiers in antibiotic alternative for Clostridioides difficile infection

Reviewer's code: 05384570 Position: Peer Reviewer Academic degree: MBBS Professional title: Doctor

Reviewer's Country/Territory: Malaysia

Author's Country/Territory: Thailand

Manuscript submission date: 2021-03-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-21 09:00

Reviewer performed review: 2021-03-27 12:12

**Review time:** 6 Days and 3 Hours

Scientific quality	[ Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous  Conflicts-of-Interest: [ ] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## SPECIFIC COMMENTS TO AUTHORS

This is an overall good and comprehensive review. I just have a few suggestions: 1. Use of certain antibiotics including clindamycin, cephalosporins, quinolones, and penicillins has been reported to increase CDI risk - This statement requires citation and further explanation. 2. The pathogenesis and toxins of C. difficile can be further elaborated and make it into a section. 3. Findings should be added into Table 1 4. Authors should add in a section on the efficacy of different antibiotics available in treating C. difficile infection which can justify the need of alternatives to antibiotics.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 66118

**Title:** Frontiers in antibiotic alternative for Clostridioides difficile infection

Reviewer's code: 05232520 Position: Editorial Board

Academic degree: BSc, MSc, PhD

Professional title: Professor, Research Scientist

Reviewer's Country/Territory: Brazil

Author's Country/Territory: Thailand

Manuscript submission date: 2021-03-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-22 12:06

Reviewer performed review: 2021-03-31 15:06

**Review time:** 9 Days and 3 Hours

Scientific quality	[ Y] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [ ] Anonymous [ Y] Onymous  Conflicts-of-Interest: [ ] Yes [ Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

**E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

## SPECIFIC COMMENTS TO AUTHORS

The manuscript submitted by Pranchana and cols., aims to critically overview and discuss alternatives to antibiotic to treat Clostridioides difficile infection. In general, the text is well written and structured. Further, the review presents a broad and in-depth critical analysis of data besides debating pros and cons of each suggested approach. Major concerns: • The authors must address the concept of eubiosis and dysbiosis rather than solely stating that "microbiota is perturbed" or "healthy microbiota" • It is of utmost importance to describe/discuss the contribution of multidrug-resistant microorganisms to safety and feasibility of FMT Minor concerns: • Please, replace the term "flora" by "microbiota"; • There are some typos throughout the text e.g: "synbiotic"